| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
REYON Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩14,560.00 |
| 52 Week High | ₩18,450.00 |
| 52 Week Low | ₩11,170.00 |
| Beta | 1.03 |
| 11 Month Change | -0.68% |
| 3 Month Change | -2.22% |
| 1 Year Change | -11.81% |
| 33 Year Change | -74.90% |
| 5 Year Change | 12.94% |
| Change since IPO | 37.41% |
Recent News & Updates
Recent updates
There May Be Reason For Hope In REYON Pharmaceutical's (KRX:102460) Disappointing Earnings
Mar 31
Consider This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For The 1.6% Dividend
May 08Here's Why REYON Pharmaceutical (KRX:102460) Has A Meaningful Debt Burden
Apr 09What Percentage Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Shares Do Insiders Own?
Feb 28Read This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For Its Dividend
Jan 20
REYON Pharmaceutical (KRX:102460) Seems To Use Debt Quite Sensibly
Jan 02Did REYON Pharmaceutical's (KRX:102460) Share Price Deserve to Gain 50%?
Dec 12How Much Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Do Insiders Own?
Nov 24Shareholder Returns
| A102460 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 19.2% | 14.1% | 7.9% |
| 1Y | -11.8% | 5.0% | -0.5% |
Return vs Industry: A102460 underperformed the KR Pharmaceuticals industry which returned 2.3% over the past year.
Return vs Market: A102460 underperformed the KR Market which returned -2.4% over the past year.
Price Volatility
| A102460 volatility | |
|---|---|
| A102460 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A102460 has not had significant price volatility in the past 3 months.
Volatility Over Time: A102460's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1955 | 463 | Soon-Ock Jung | reyonpharm.co.kr |
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study.
REYON Pharmaceutical Co., Ltd. Fundamentals Summary
| A102460 fundamental statistics | |
|---|---|
| Market cap | ₩267.04b |
| Earnings (TTM) | ₩1.92b |
| Revenue (TTM) | ₩151.06b |
139.0x
P/E Ratio1.8x
P/S RatioIs A102460 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A102460 income statement (TTM) | |
|---|---|
| Revenue | ₩151.06b |
| Cost of Revenue | ₩75.32b |
| Gross Profit | ₩75.73b |
| Other Expenses | ₩73.81b |
| Earnings | ₩1.92b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 104.73 |
| Gross Margin | 50.13% |
| Net Profit Margin | 1.27% |
| Debt/Equity Ratio | 90.2% |
How did A102460 perform over the long term?
See historical performance and comparison